Jeffrey Friedman
Board Member @Trio Pharmaceuticals, Inc
Signup · Get unlimited contacts
WORK HISTORY
Board Member @Trio Pharmaceuticals, Inc
San Diego, CA, US
Trio Pharma is working on a family of chimeric biologic drugs for the treatment of cancer. Trio\'s approach combines a tumor specific antigen binder with a death domain activator to specifically localize to, and kill tumor cells. The chimeric molecules are also designed to interact with and eliminate tumor localized MDSC in order to overcome a block to immune function that allows many difficult to treat tumors evade immune mediated cell death.
EDUCATION
Massachusetts Institute of Technology
Bachelor of Science (BS), Biology/Biological Sciences, General
Stanford University
Doctor of Philosophy (Ph.D.), Cancer Biology
Dana Farber Cancer Institute
Fellowship, Pediatric Hematology-Oncology Research
Boston Children's Hospital
Internship/Residency, Pediatrics Residency Program
Stanford University School of Medicine
Doctor of Medicine (MD), Medicine
SKILLS
ABOUT JEFFREY FRIEDMAN
FriedmanBioventure invests in early stage companies with promising technologies. Several areas are of interest: Genomics/nexGen sequencing, Neurodegenerative disease, Mitochondrial disorders, Platform technologies that speed drug development. Our portfolio includes more than 50 early stage companies. Thus far, we have led or co-led four Seed or Series A financings: DTx Pharma in 2019 where a total of $10.6 million was raised, including a significant investment from Eli Lilly and Company; PetDx in 2020 with a total round size ~$9 million, including participation from key strategic investors; Trio Pharma in 2022 along with Seed Folio and Nufund, which raised ~$2.2 million, Hillhurst Biopharma in 2023 which raised ~1.8M, and Trio Pharma which has just closed on an additional $3.1M as part of a planned $6M pre-Series A financing in November of 2024. We expect many of our portfolio companies to advance programs and access capital during 2024-5, and will be selectively leading and participating in additional financing rounds.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.